Navigation Links
PURE Bioscience CEO to Ring NASDAQ Closing Bell
Date:7/11/2008

SAN DIEGO, July 11 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) announced today that Michael L. Krall, the company's president and CEO, is scheduled to ring the closing bell at the NASDAQ Stock Exchange at 4:00 PM on Tuesday, July 15, 2008, to commemorate PURE's return to the NASDAQ stock market on April 2, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

A live webcast of the closing ceremony will begin at 3:50 PM and can be viewed via The MarketSite Webcam by launching this link: http://www.nasdaq.com/about/marketsitetowervideo.asx.

Earlier this month, PURE entered into an agreement with FTA Therapeutics, LLC for the development and licensing of silver dihydrogen citrate (SDC)-based products for clinical projects for FDA-regulated dermatology, wound care and medical biofilm control products. In April, PURE announced a partnership with Rockline Industries Inc, for North American distribution of PURE's ready-to-use "Powered by SDC" disinfectant product and for the development and North American distribution of wipes products, as well as new disinfectant, sanitizer and preservative products containing the company's patented antimicrobial, silver dihydrogen citrate (SDC).

"Powered by SDC(TM)"

SDC, PURE Bioscience's flagship technology, is the first new disinfectant active to be registered by the EPA in more than 30 years, and "Powered by SDC" disinfectants combine extraordinary broad spectrum antimicrobial action with a previously unattainable safety profile. SDC is a patented, aqueous non-toxic antimicrobial, which is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. PURE also manufactures and sells varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third-party products.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Paul G. Henning, Vice President

Cameron Associates

212 554 5462

paul@cameronassoc.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... of advanced software solutions for pharmaceutical research and development (R&D), today announced ... in omic data analysis and interpretation for the rapidly evolving field of ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... National Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, the ... element of grant applications subject to the existing policy. AMIA recommended that NIH ...
(Date:1/19/2017)... 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW ... therapies for operable and inoperable solid tumor cancers, announced ... Officer of NW Bio, will present at the Phacilitate ... the Hyatt Regency Hotel in Miami, Florida ... session entitled "New Therapeutic Approaches – Expanding the Reach ...
(Date:1/18/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, will feature data from two clinical studies ... ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in ... Napabucasin is an orally-administered investigational agent designed to inhibit ... stem cells (CSCs) possess the property of stemness – ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... provider, today announced an agreement with NuData Security, an ... forces. The partnership will enable clients to focus on good ... local data protection regulation. ... In order to provide a one-stop fraud ...
(Date:12/15/2016)... ... Research and Markets has announced the addition of the "Global ... The report forecasts the global military biometrics market to grow at a ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
Breaking Biology News(10 mins):